Autumn Fruits in Nanjing: A Grand Gathering in the Medical Field! From November 19 to 21, 2025, the highly anticipated 91st National Pharmaceutical Trade Fair (PHARMCHINA) was grandly held at the Nanjing International Expo Center. Themed "Building a New Ecosystem for Innovation and Co-development in the Pharmaceutical and Health Industry," the fair featured diverse exhibition zones covering chemical drugs, traditional Chinese medicine, medical devices, pharmaceutical R&D, supply chains, and more. It served both as a comprehensive showcase of achievements in the pharmaceutical and health industry and as a central hub for efficient resource connection across the entire industrial chain. As a key player deeply rooted in the industry, Sinopharm Central Health made a prominent appearance with its powerful product portfolio, engaging with industry peers in a professional manner to discuss innovation opportunities and jointly chart a new blueprint for a Healthy China.
Heavyweight Presence, Core Strength on Display
At the opening ceremony, Mr. Ma Dongsheng, Director of the Commercial Department of Sino Universal Pharma, was invited to attend the launch ceremony and jointly unveiled the event together with industry leaders and renowned entrepreneur representatives. This significant participation not only reflects the industry's high recognition of Sinopharm Central Health's position but also demonstrates the company's profound influence in deeply cultivating the pharmaceutical field and connecting industrial resources.
Product Portfolio in Focus, Health Protected by Expertise
Within the exhibition area of Sinopharm Central Health, the achievements of three core product pipelines were prominently showcased, forming a "full-cycle, multi-dimensional" product matrix—covering three major categories: products selected in national volume-based procurement, products for procurement extension, and products not included in centralized procurement. More than thirty approved products were displayed alongside dozens of pipeline projects awaiting market launch, comprehensively addressing core clinical needs.
Policy Alignment: The eleventh round of national volume-based procurement selected product, Dapagliflozin Tablets, closely aligns with industry policy direction. With its high cost-effectiveness and clinical value, it became a focal point of the exhibition area, attracting numerous inquiries and discussions from both new and existing clients.
Continuity Assurance: For the first to eighth rounds of national procurement extension, 16 products across 25 specifications drew significant attention from partners due to their stable supply system and mature clinical application foundation. Together, attendees explored market opportunities during the policy transition period.
Differentiated Advantages: Products such as Lansoprazole Orally Disintegrating Tablets (unique dosage form), Tizanidine Hydrochloride Tablets, Teriflunomide Tablets, Fampridine Extended-Release Tablets, and Atazanavir Sulfate Capsules (some of which are exclusive varieties)—leveraging their scarce dosage forms, exclusive qualifications, and high clinical value—continuously captured industry attention and served as the "pillars of strength" within the exhibition area.
During the exhibition, Mr. Yu Dunyang, Director of the Human Resources Department of Sinopharm Central Health, provided a comprehensive briefing to Mr. Li Chao, Chairman of Sinopharm Exhibitions, and Ms. Zheng Xiaoming, Deputy Secretary-General of the Nanjing Municipal People's Government, along with their delegations who visited the exhibition area. He reported on Sinopharm Central Health's core product advantages, full-chain industrial layout, and progress in global cooperation. The company's forward-looking strategy and development potential received high recognition and full praise from the leaders.
Mr. Li Wang, Chairman of Sinopharm Central Health, personally visited the exhibition venue and, together with the marketing team, received partners from both domestic and international markets. Guided by the principles of "a solid product matrix as the foundation, cutting-edge industry insights as the wings, and warm-hearted service as the bridge," the team deeply listened to customer needs, accurately captured market dynamics, and achieved a harmonious alignment between product value and market demand.
The blueprint is already laid out, and the time for action is now.
At present, the pharmaceutical industry stands at a critical inflection point where old and new drivers of growth are being transformed. "Building a new ecosystem for innovation and co-development" has become the core proposition for breaking new ground in the sector. Sino Universal Pharma will continue to deepen its dual-driven model of "global sourcing + self-driven R&D," further improve the full-industry-chain layout, accelerate the pace of international collaboration, and build a win-win ecosystem of partnerships for innovation. Looking ahead, we will always uphold our corporate values of "dedication, focus, value, and altruism." Guided by the "Healthy China" strategy, we will walk shoulder to shoulder with industry peers to jointly forge a new future of high-quality development for the pharmaceutical and health industry.